David Devos

Summary

Affiliation: CHRU de Lille
Country: France

Publications

  1. pmc Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
    Caroline Moreau
    Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 84:552-5. 2013
  2. doi Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease
    David Devos
    INSERM French National Institute of Medical Research and Health, APHP Assistance Publique Hôpitaux de Paris, Clinical Investigation Center CIC 9503, Pitie Salpetriere Hospital, Paris, France Lille Nord de France University, Department of Medical Pharmacology, Lille University Medical Center, Faculty of Medicine of Lille 2, EA 4610, France Electronic address
    Parkinsonism Relat Disord 20:170-5. 2014
  3. ncbi New pharmacological options for treating advanced Parkinson's disease
    David Devos
    Department of Medical Pharmacology, EA 1046, Lille Nord de France University, Lille, France Electronic address
    Clin Ther 35:1640-52. 2013
  4. doi Methylphenidate : a treatment for Parkinson's disease?
    David Devos
    Department of Medical Pharmacology, EA 1046, Lille Nord de France University, CHU Lille, Lille, France
    CNS Drugs 27:1-14. 2013
  5. doi Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia
    Sophie Tezenas du Montcel
    Department of Biostatistics and Medical Informatics, and Pitié Salpêtrière Charles Foix Clinical Research Unit, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, Paris, France
    Arch Neurol 69:500-8. 2012
  6. ncbi Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial
    David Devos
    Department of Medical Pharmacology, Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 85:668-74. 2014
  7. doi Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study
    David Devos
    Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France
    Mov Disord 23:850-7. 2008
  8. ncbi Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients
    Melissa Tir
    Department of Neurology, Salengro Hospital, Lille University Medical Centre, Lille, France
    Neurosurgery 61:297-304; discussion 304-5. 2007
  9. doi Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
    Caroline Moreau
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France
    Lancet Neurol 11:589-96. 2012
  10. ncbi Effect of intermittent theta-burst stimulation on akinesia and sensorimotor integration in patients with Parkinson's disease
    Adrian Degardin
    Universite Lille Nord de France, EA 4559, CHRU de Lille, Hopital Roger Salengro, F 59037 Lille Cedex, France
    Eur J Neurosci 36:2669-78. 2012

Detail Information

Publications32

  1. pmc Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study
    Caroline Moreau
    Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 84:552-5. 2013
    ..Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD)...
  2. doi Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease
    David Devos
    INSERM French National Institute of Medical Research and Health, APHP Assistance Publique Hôpitaux de Paris, Clinical Investigation Center CIC 9503, Pitie Salpetriere Hospital, Paris, France Lille Nord de France University, Department of Medical Pharmacology, Lille University Medical Center, Faculty of Medicine of Lille 2, EA 4610, France Electronic address
    Parkinsonism Relat Disord 20:170-5. 2014
    ..In Parkinson's disease (PD), the response to L-dopa is highly variable and unpredictable. The major pathway for dopamine synthesis from L-dopa is decarboxylation by aromatic L-amino acid decarboxylase (AAAD, encoded by the DDC gene)...
  3. ncbi New pharmacological options for treating advanced Parkinson's disease
    David Devos
    Department of Medical Pharmacology, EA 1046, Lille Nord de France University, Lille, France Electronic address
    Clin Ther 35:1640-52. 2013
    ..Fourthly, there is a need for disease- modifying treatments (DMTs) that slow disease progression and reduce the occurrence of the very disabling disorders seen in late-stage PD...
  4. doi Methylphenidate : a treatment for Parkinson's disease?
    David Devos
    Department of Medical Pharmacology, EA 1046, Lille Nord de France University, CHU Lille, Lille, France
    CNS Drugs 27:1-14. 2013
    ..Pharmacogenetic tools could be of use in better defining study patients as a function of their dopaminergic metabolism and drug responsiveness...
  5. doi Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia
    Sophie Tezenas du Montcel
    Department of Biostatistics and Medical Informatics, and Pitié Salpêtrière Charles Foix Clinical Research Unit, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, Paris, France
    Arch Neurol 69:500-8. 2012
    ..To evaluate disease progression and determine validity of clinical tools for therapeutic trials...
  6. ncbi Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial
    David Devos
    Department of Medical Pharmacology, Lille University Hospital, Lille, France
    J Neurol Neurosurg Psychiatry 85:668-74. 2014
    ..We sought to establish whether rivastigmine's ability to inhibit acetyl- and butyrylcholinesterases could relieve the symptoms of apathy in dementia-free, non-depressed patients with advanced PD...
  7. doi Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study
    David Devos
    Department of Neurology, IFR114, Institute of Predictive Medicine and Therapeutic Research, Lille University Hospital, Lille, France
    Mov Disord 23:850-7. 2008
    ..A predominantly noradrenergic tricyclic antidepressant induced a more intense short-term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short-term clinical advantage...
  8. ncbi Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients
    Melissa Tir
    Department of Neurology, Salengro Hospital, Lille University Medical Centre, Lille, France
    Neurosurgery 61:297-304; discussion 304-5. 2007
    ..The primary objective was to describe the clinical outcome in terms of efficacy and tolerance in STN-DBS patients. A secondary objective was to discuss presurgery clinical characteristics a posteriori as a function of outcome...
  9. doi Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
    Caroline Moreau
    Department of Movement Disorders and Neurology, Lille Nord de France University, CHU Lille, Lille, France
    Lancet Neurol 11:589-96. 2012
    ....
  10. ncbi Effect of intermittent theta-burst stimulation on akinesia and sensorimotor integration in patients with Parkinson's disease
    Adrian Degardin
    Universite Lille Nord de France, EA 4559, CHRU de Lille, Hopital Roger Salengro, F 59037 Lille Cedex, France
    Eur J Neurosci 36:2669-78. 2012
    ..No changes in SAI and LAI were observed. Our data suggest that iTBS might improve both akinesia and sensory processing in patients with PD taking levodopa...
  11. doi Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias
    Ellis Chan
    Department of Biostatistics and Medical Informatics and Pitié Salpêtrière Charles Foix Clinical Research Unit, AP HP, Paris, France
    Mov Disord 26:534-8. 2011
    ..Responsive ataxia rating scales are essential for determining outcome measures in clinical trials...
  12. doi Spinocerebellar ataxia: a rational approach to aetiological diagnosis
    Adrian Degardin
    Department of Neurology, EA 2683, IMPRT, IFR114, Universite Lille Nord de France, CHRU, Lille, France
    Cerebellum 11:289-99. 2012
    ..Ophthalmological examination was the most helpful physiological assessment...
  13. ncbi The pattern of attentional deficits in Parkinson's disease
    Kathy Dujardin
    Laboratoire de Neurosciences Fonctionnelles et Pathologies, EA 4559, University of Lille 2, Lille, France
    Parkinsonism Relat Disord 19:300-5. 2013
    ..We also sought to identify the main demographic and clinical characteristics associated with attention deficits in Parkinson's disease...
  14. doi Parkinson's disease dementia can be easily detected in routine clinical practice
    Kathy Dujardin
    Universite Lille Nord de France, UDSL, CNRS FRE3291, Neurology and Movement Disorders Unit, Lille University Medical Center, Lille, France
    Mov Disord 25:2769-76. 2010
    ....
  15. ncbi Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease
    David Devos
    Department of Neurology and Movement Disorders, EA2683, IMPRT, IFR 114, Faculty of Medicine Lille 2, University of Lille Nord de France, Lille University Hospital, Lille, France
    Fundam Clin Pharmacol 24:407-21. 2010
    ..The goal of this review is to develop the various pathophysiological hypotheses published to date, in order to underpin and justify ongoing fundamental research and clinical trials in this disease area...
  16. ncbi Neurodegeneration with brain iron accumulation: clinical, radiographic and genetic heterogeneity and corresponding therapeutic options
    Frederik Clement
    Department of Neurology, Hopital Roger Salengro, Lille, France
    Acta Neurol Belg 107:26-31. 2007
    ..Neurodegeneration with brain iron accumulation (NBIA), formerly known as Hallervorden-Spatz syndrome, is a heterogeneous group of disorders with different treatment options...
  17. ncbi Benign hereditary chorea: phenotype, prognosis, therapeutic outcome and long term follow-up in a large series with new mutations in the TITF1/NKX2-1 gene
    Domitille Gras
    AP HP, Service de Neuropediatrie, Hopital Trousseau, Paris, France
    J Neurol Neurosurg Psychiatry 83:956-62. 2012
    ..The aim of the study was to refine the movement disorders phenotype. We also studied disease course and response to therapy in a large series of genetically proven patients...
  18. ncbi Characteristics of apathy in Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, EA2683, Faculty of Medicine and Lille University Hospital, Lille, France
    Mov Disord 22:778-84. 2007
    ..Although the neurochemical substrate of apathy remains poorly characterized, the strong link between apathy and cognitive impairment observed in several studies suggests the participation of nondopaminergic circuits...
  19. doi Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
    David Devos
    Department of Neurology, EA2683 IFR114 IMPRT, Hopital R Salengro, CHU Lille, France
    Mov Disord 24:993-1000. 2009
    ..Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last-line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered...
  20. ncbi Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: A magnetic resonance imaging shape analysis
    Nicolas Carriere
    Service de Neurologie et Pathologie du Mouvement, Centre Hospitalier Regional Universitaire, Lille, France Université Lille Nord de France, EA 1046, Lille, France
    Mov Disord 29:897-903. 2014
    ..Dopa-resistant apathy in PD was associated with atrophy of the left nucleus accumbens and the dorsolateral head of the left caudate. © 2014 International Parkinson and Movement Disorder Society. ..
  21. ncbi Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease
    Kathy Dujardin
    Neurology and Movement Disorders Unit, Faculty of Medicine and Lille University Hospital, EA2683, Lille, France
    J Neurol 253:1154-9. 2006
    ....
  22. pmc Phenotypic variability in ARCA2 and identification of a core ataxic phenotype with slow progression
    Cyril Mignot
    Department of Genetics and Cytogenetics, AP HP, Hopital de la Salpetriere, Paris, F 75013, France
    Orphanet J Rare Dis 8:173. 2013
    ..e. low ubiquinone level or functional evidence of ubiquinone deficiency. This diagnosis is crucial since the neurological status of some patients may be improved by ubiquinone therapy. ..
  23. doi Deficit of sensorimotor integration in normal aging
    Adrian Degardin
    Universite Lille Nord de France, CHRU de Lille, Neurophysiologie Clinique, Hopital Roger Salengro, F 59037 Lille Cedex, France
    Neurosci Lett 498:208-12. 2011
    ..Decreased sensorimotor performance with aging appears to be associated with a decrease in the influence of proprioceptive inputs on motor cortex excitability at longer intervals (probably via higher order cortical areas)...
  24. doi CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients
    Caroline Moreau
    Service de Neurologie et Pathologie du Mouvement, Hopital Roger Salengro, CHRU, Lille, France
    Amyotroph Lateral Scler 10:175-81. 2009
    ..Our results suggest alteration of the HIF-1alpha-mediated response to hypoxia during sporadic ALS, whereas the NFK-B pathway seems early activated...
  25. pmc Targeting chelatable iron as a therapeutic modality in Parkinson's disease
    David Devos
    1 Department of Medical Pharmacology, Faculté de Médecine Lille2, Lille Nord de France University, CHU Lille, Lille, France
    Antioxid Redox Signal 21:195-210. 2014
    ..Antioxid. Redox Signal. 21, 195-210. ..
  26. doi Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment
    Sophie Tezenas du Montcel
    AP HP, Department of Biostatistics and Medical Informatics, Pitié Salpêtrière Charles Foix Clinical Research Unit, University Pierre et Marie Curie, Paris, France
    Brain 131:1352-61. 2008
    ....
  27. doi Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours
    Marie Bodenant
    Department of Neurology, University Hospital of Lille, Lille, France
    Cerebrovasc Dis 30:148-56. 2010
    ..Stroke outcomes are worse in patients admitted at nonworking hours (NWH), but whether this is also true in patients treated with intravenous (i.v.) thrombolysis has not been definitely proven...
  28. doi Thickening of peripapillar retinal fibers for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay
    Jeremy Desserre
    Service d Exploration de la Vision et Neuro Ophtalmologie, Hopital Roger Salengro, Lille, France
    Cerebellum 10:758-62. 2011
    ..This ophthalmological consideration has avoided misdiagnosis and led to the description of new mutations in our cases...
  29. doi Spectrum of movement disorders associated with glutaric aciduria type 1: a study of 16 patients
    Cyril Gitiaux
    Universite Paris Descartes, Service de Neurologie Pediatrique et Maladies Metaboliques, Hopital Necker Enfants Malades, AP HP, Paris, France
    Mov Disord 23:2392-7. 2008
    ..The types and outcome of movement disorders in this setting should be taken into consideration during rehabilitation and for patient selection and evaluation in therapeutic trials...
  30. ncbi Abnormal cortical mechanisms in voluntary muscle relaxation in de novo parkinsonian patients
    Etienne Labyt
    Department of Clinical Neurophysiology, R Salengro Hospital, Lille University Medical Center, Lille Cedex, France
    J Clin Neurophysiol 22:192-203. 2005
    ..The authors suggest that this may be due to anomalous activity in inhibitory motor cortical systems and impaired sensorimotor integration of afferent inputs from muscle and joint receptors...
  31. ncbi Relationship between oscillations in the basal ganglia and synchronization of cortical activity
    Francois Cassim
    Service de Neurophysiologie Clinique, Hopital Roger Salengro, CHRU de Lille, 59037 Lille Cedex, France
    Epileptic Disord 4:S31-45. 2002
    ..Studies of cortical reactivity related to planning of voluntary movement in parkinsonian patients provide evidence that it is possible to influence cortical reactivity through the basal ganglia system...
  32. doi Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene
    Bernard Puech
    Service d Exploration de la Vision et Neuro Ophtalmologie, Hopital Roger Salengro, CHRU de Lille, Lille Cedex, France
    Ophthalmology 118:564-73. 2011
    ..A 10-year ophthalmologic and neurologic follow-up of 5 patients allowed us to describe the disease's characteristics, early symptoms and progression, associated ocular signs, and retinal changes in carriers...